Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2017-03-03 Report Publication Anno…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a press release dated March 3, 2017, announcing that Bone Therapeutics will publish its 2016 financial results on March 16, 2017. It details the time and method for accessing the conference call where management will present these results. Since the document is an announcement about the future publication of financial results (the actual results report), and not the results themselves (like an ER or IR), it fits the definition of a Report Publication Announcement (RPA). The document length (6487 chars) is substantial, but its primary function is to announce the release date and access details for the upcoming financial report, aligning perfectly with the RPA definition.
2017-03-03 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Management Reports Classification · 95% confidence The document is a quarterly activity report ('rapport d'activité du quatrième trimestre 2016') issued by Bone Therapeutics. It provides a summary of operational progress, clinical trial updates, management changes, and financial highlights (cash position). While it contains financial information, it is not a full 10-K or a formal interim financial report (IR) but rather a management-led quarterly update. Given the structure and content, it fits best as a Management Report (MDA) detailing business trends and outlook for the period.
2017-01-17 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a business update press release from Bone Therapeutics for Q4 2016. It provides operational highlights, financial highlights (unaudited cash position), and an outlook for 2017. It is not a full quarterly report (IR) as it is a summary announcement, nor is it an earnings release (ER) as it focuses on business updates rather than a formal earnings statement. It fits best as a general regulatory announcement (RNS) for corporate updates.
2017-01-17 English
Bone Therapeutics Provides Business Update for Q4 2016
Earnings Release Classification · 98% confidence The document is titled 'Bone Therapeutics Provides Business Update for Q4 2016' and is dated January 17, 2017. It details operational highlights, corporate changes (CEO appointment), funding received, and financial highlights for the fourth quarter of 2016. Crucially, it mentions that 'The full 2016 Annual Results will be announced on March 16, 2017.' This indicates the document is a summary or update preceding the full Annual Report (10-K). Since it provides key financial highlights and operational summaries for a completed period (Q4 2016), it aligns best with an Earnings Release (ER), which typically precedes the comprehensive annual filing. It is not the full 10-K, nor is it a transcript (CT) or a presentation (IP). It is a formal announcement of period results/update. Q4 2016
2017-01-17 English
Bone Therapeutics publie son rapport d’activité du T4 2016
Earnings Release Classification · 98% confidence The document is titled "Bone Therapeutics publie son rapport d'activité du T4 2016" (Bone Therapeutics publishes its Q4 2016 activity report). It provides a summary of operational achievements, key financial figures (cash position, net cash burn) for the period ending December 31, 2016, and outlook for 2017. This content structure—a summary of operational and financial highlights for a specific period, often released before the full statutory report—is characteristic of an Earnings Release (ER). Although it mentions the 'rapport d'activité' (activity report), the text itself functions as the initial announcement of results, not the comprehensive annual report (10-K) or a comprehensive interim report (IR). Furthermore, it explicitly states: "Les résultats annuels 2016 seront publiés le 16 mars 2017," confirming this document is the preliminary announcement, not the final annual filing. Q4 2016
2017-01-17 French
Bone Therapeutics Business Update Vierde Kwartaal 2016
Earnings Release Classification · 98% confidence The document is titled "Bone Therapeutics Business Update Vierde Kwartaal 2016" and is dated January 17, 2017. It provides a business overview and financial highlights for the fourth quarter ending December 31, 2016. Key elements include operational updates (clinical trial progress, strategic focus changes), corporate changes (CEO appointment), and financial summaries (cash position, cash burn). This structure—a summary of recent performance and key operational/financial metrics for a specific past period (Q4 2016)—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on the *update* and *highlights* for the quarter, rather than being a comprehensive, detailed financial statement typical of a full 10-Q or 10-K, it aligns best with an Earnings Release (ER). The document explicitly states that the full year figures for 2016 will be announced later (March 16, 2017), reinforcing that this is an interim/quarterly summary. Q4 2016
2017-01-17 Dutch

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.